Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The interface allows researchers to transition benchwork to an autonomous lab infrastructure through a web browser.
March 2, 2026
By: Patrick Lavery
Content Marketing Editor
Ginkgo Bioworks is officially launching its Ginkgo Cloud Lab. This new interface will let researchers transition their benchwork to Ginkgo’s autonomous lab infrastructure, directly through a web browser.
Ginkgo Bioworks’ goal, eventually, is to move its R&D services onto that autonomous lab, Nebula, in Boston. By doing this, the company hopes to decommission traditional lab benches, instead favoring programmable robotic infrastructure.
Scientists can visit cloud.ginkgo.bio to submit their specific protocols for development on the Cloud Lab. Following submission, they receive a feasibility report and price quote. Anyone from academia to global pharmaceutical companies can submit.
Ginkgo Bioworks says a scientist submitting a protocol in human language and getting an immediate compatibility assessment is unprecedented.
Making it possible is an AI-driven agent, EstiMate. Furthermore, the Cloud Lab runs on Ginkgo Bioworks’ proprietary Reconfigurable Automation Carts. These feature high-precision robotic arms, maglev sample transport tracks, and industrial-grade software.
Ginkgo Bioworks CEO Jason Kelly offered some thoughts on the launch.
“Autonomous labs are poised to scale and accelerate the high-mix work that a lab bench supports,” Kelly said. “By opening up our autonomous infrastructure through the Cloud Lab, we’re giving scientists access to these tools today.”
In November 2025, Ginkgo Bioworks garnered a contract through the Biomedical Advanced Research and Development Authority’s Biopharmaceutical Manufacturing Preparedness Consortium. This contract ultimately strengthens, and reduces costs of, domestic biomanufacturing of monoclonal antibodies protecting against filovirus infection.
Earlier in 2025, the company was awarded another contract, this one with the Advanced Research Projects Agency for Health. Partners included Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by Donaldson.
That two-year program is known as Wheat-based High-efficiency Enzyme and API Technology (WHEAT). It involves a manufacturing process for producing biologic and small-molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
